ES 006
Alternative Names: ES-006Latest Information Update: 28 Apr 2023
At a glance
- Originator Elpiscience Biopharmaceuticals
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for research development in Cancer in China (Parenteral)
- 19 Mar 2019 ES 006 is available for licensing as of 19 Mar 2019. (http://www.elpiscience.com/index.php?c=article&a=type&tid=416)
- 19 Mar 2019 Early research in Cancer in China (Parenteral) before March 2019 (Elpiscience Biopharmaceuticals pipeline, March 2019)